Tag

NASDAQ: VIR

Vir Biotechnology meets Phase 3 hepatitis delta endpoint with 44% response
Adrian Kessler · Nov 8, 2026
Arbutus Biopharma says FDA lifts AB‑101 clinical hold
Adrian Kessler · Oct 22, 2026
Vir Biotechnology signs Gilead cancer deal with US$90M upfront
Adrian Kessler · Oct 15, 2026